Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis.

Li LS, Morales JC, Hwang A, Wagner MW, Boothman DA.

J Biol Chem. 2008 Aug 1;283(31):21394-403. doi: 10.1074/jbc.M709954200. Epub 2008 May 14.

2.

MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine.

Sun G, Jin S, Baskaran R.

Exp Cell Res. 2009 Nov 1;315(18):3163-75. doi: 10.1016/j.yexcr.2009.09.010. Epub 2009 Sep 17.

3.

Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses.

Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG, Boothman DA.

J Biol Chem. 2008 Aug 1;283(31):21382-93. doi: 10.1074/jbc.M709953200. Epub 2008 May 14.

4.
5.
6.

Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis.

Agami R, Blandino G, Oren M, Shaul Y.

Nature. 1999 Jun 24;399(6738):809-13.

PMID:
10391250
7.

Mismatch repair-dependent transcriptome changes in human cells treated with the methylating agent N-methyl-n'-nitro-N-nitrosoguanidine.

di Pietro M, Marra G, Cejka P, Stojic L, Menigatti M, Cattaruzza MS, Jiricny J.

Cancer Res. 2003 Dec 1;63(23):8158-66.

8.

Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.

Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA.

Cancer Res. 2001 Jul 1;61(13):5193-201.

9.

A positive role for c-Abl in Atm and Atr activation in DNA damage response.

Wang X, Zeng L, Wang J, Chau JF, Lai KP, Jia D, Poonepalli A, Hande MP, Liu H, He G, He L, Li B.

Cell Death Differ. 2011 Jan;18(1):5-15. doi: 10.1038/cdd.2010.106. Epub 2010 Aug 27.

10.

Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2.

Adamson AW, Beardsley DI, Kim WJ, Gao Y, Baskaran R, Brown KD.

Mol Biol Cell. 2005 Mar;16(3):1513-26. Epub 2005 Jan 12.

11.

c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association.

Ben-Yehoyada M, Ben-Dor I, Shaul Y.

J Biol Chem. 2003 Sep 5;278(36):34475-82. Epub 2003 Jun 24.

12.

Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase.

Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G, Jiricny J.

Genes Dev. 2004 Jun 1;18(11):1331-44.

13.

Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation.

Yan T, Schupp JE, Hwang HS, Wagner MW, Berry SE, Strickfaden S, Veigl ML, Sedwick WD, Boothman DA, Kinsella TJ.

Cancer Res. 2001 Nov 15;61(22):8290-7.

14.

Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells.

Qi Y, Schoene NW, Lartey FM, Cheng WH.

J Biol Chem. 2010 Oct 22;285(43):33010-7. doi: 10.1074/jbc.M110.137406. Epub 2010 Aug 6.

15.

RAD51D protects against MLH1-dependent cytotoxic responses to O(6)-methylguanine.

Rajesh P, Rajesh C, Wyatt MD, Pittman DL.

DNA Repair (Amst). 2010 Apr 4;9(4):458-67. doi: 10.1016/j.dnarep.2010.01.009. Epub 2010 Feb 4.

16.

Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.

Bhonde MR, Hanski ML, Stehr J, Jebautzke B, Peiró-Jordán R, Fechner H, Yokoyama KK, Lin WC, Zeitz M, Hanski C.

Int J Cancer. 2010 Jun 15;126(12):2813-25. doi: 10.1002/ijc.24893.

17.

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations.

Stoklosa T, Poplawski T, Koptyra M, Nieborowska-Skorska M, Basak G, Slupianek A, Rayevskaya M, Seferynska I, Herrera L, Blasiak J, Skorski T.

Cancer Res. 2008 Apr 15;68(8):2576-80. doi: 10.1158/0008-5472.CAN-07-6858.

18.

ATM is activated in response to N-methyl-N'-nitro-N-nitrosoguanidine-induced DNA alkylation.

Adamson AW, Kim WJ, Shangary S, Baskaran R, Brown KD.

J Biol Chem. 2002 Oct 11;277(41):38222-9. Epub 2002 Jul 31.

19.
20.

Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.

Aquilina G, Ceccotti S, Martinelli S, Soddu S, Crescenzi M, Branch P, Karran P, Bignami M.

Clin Cancer Res. 2000 Feb;6(2):671-80.

Items per page

Supplemental Content

Write to the Help Desk